Share This Page
HYDRO-SERP 50 Drug Patent Profile
✉ Email this page to a colleague
When do Hydro-serp 50 patents expire, and what generic alternatives are available?
Hydro-serp 50 is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in HYDRO-SERP 50 is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
US Patents and Regulatory Information for HYDRO-SERP 50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | HYDRO-SERP 50 | hydrochlorothiazide; reserpine | TABLET;ORAL | 085213-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Investment scenario and fundamentals analysis for HYDRO-SERP 50 (Hydrochlorothiazide 50 mg with Reserpine 0.5 mg)
Executive summary: HYDRO-SERP 50 is a fixed-dose antihypertensive combination product (hydrochlorothiazide 50 mg + reserpine 0.5 mg). The investment case is dominated by (1) patent and regulatory exclusivity structure in each target market, (2) competitive pressure from generic antihypertensives and alternative combination therapies, and (3) supply-chain and labeling risks tied to an older, off-patent regimen. In practical terms, long-term value retention hinges less on proprietary technology and more on brand-level demand stability, distribution entrenchment, and regulatory defensibility of the specific FDC strength and tablet formulation.
What is HYDRO-SERP 50 and how does it fit antihypertensive treatment standards?
Featured snippet answer: HYDRO-SERP 50 is a fixed-dose tablet combining hydrochlorothiazide 50 mg and reserpine 0.5 mg, used for hypertension management.
Core fundamentals that drive demand
- Clinical category: Thiazide diuretic (hydrochlorothiazide) + centrally acting depletor of monoamines (reserpine).
- Therapy role: Historically used for uncomplicated hypertension, typically as part of older guideline approaches where thiazides were foundational and reserpine added additive BP lowering.
- Modern context: Many markets have shifted to combinations using ACE inhibitors/ARBs, calcium-channel blockers, and newer diuretic strategies. That shift usually compresses brand longevity for older regimens, unless the product has entrenched formularies or low-cost procurement advantages.
Commercial demand determinants
- Formulary inclusion (public tender and reimbursement lists).
- Physician prescribing inertia in local markets.
- Unit economics: older actives generally face stronger generic price pressure.
- Safety and tolerability perception: reserpine has a higher risk profile historically associated with depression and sedation in sensitive populations, which can affect uptake when prescribers have alternative combination options.
What patents protect HYDRO-SERP 50 and how strong is the patent estate?
Featured snippet answer: Investment defensibility requires an Orange Book (US) or national registry (non-US) mapped to the exact FDC strength and the specific tablet composition/process. For HYDRO-SERP 50, a complete patent estate mapping cannot be produced from the information provided here.
Patent estate factors that matter for an investment thesis
- Composition-of-matter coverage: whether either active has any relevant late-life patents in the specific jurisdiction (usually unlikely for hydrochlorothiazide and long-expired reserpine).
- Formulation patents: patents for tablet composition, excipients, coating systems, granulation methods, or controlled-release architectures.
- Method-of-use patents: dosing regimens or patient subsets, often weak against off-label and generic substitution.
- FDC-specific exclusivity: if regulators approved a particular strength only under a protected reference product or via data exclusivity tied to a new combination.
Investment implication
- Where the drug is off-patent, the risk is not “patent litigation,” it is pricing compression and market share leakage to authorized generics and parallel imports. The base-case valuation should model a multi-generic market rather than a monopoly.
When does HYDRO-SERP 50 lose exclusivity, and what are the realistic generic entry timelines?
Featured snippet answer: A generic entry timeline for HYDRO-SERP 50 depends on exclusivity (regulatory) and patent expiration in each target geography, but this cannot be calculated from the provided input.
How to frame exclusivity risk in the absence of mapped filings
- If actives are off-patent in a market: earliest risk is immediate after regulatory approvals clear, constrained only by product-specific labeling, manufacturing authorization, and pharmacovigilance history.
- If an FDC strength is newly registered: the market often sees a short window where “same combination, different NDA/registration route” still faces data protection or local data exclusivity.
Timeline drivers for tablets
- ANDA-style entry (US) or generic registration submissions (EU/UK/selected emerging markets).
- Variations in bioequivalence requirements.
- Labeling constraints around reserpine adverse event warnings.
What is the Orange Book status of HYDRO-SERP 50 and does it support an exclusivity-based valuation?
Featured snippet answer: Orange Book status cannot be confirmed from the information provided here.
Why Orange Book status changes the investment model
- If listed: it shapes Paragraph IV leverage, settlement likelihood, and authorized generic risk.
- If not listed: valuation rests on brand economics, not legal exclusivity.
What generic entry risks exist for HYDRO-SERP 50 by active and by formulation?
Featured snippet answer: The generic entry risk is high when the market includes off-patent thiazide and reserpine, and when no formulation/process exclusivity blocks manufacturing.
Key risk channels
- Same-strength generics: hydrochlorthiazide + reserpine combinations are typically easy to replicate at tablet scale.
- Substitution risk: prescribers can switch to other antihypertensive combinations with lower perceived CNS side effects.
- Pack/label competition: even if an exact strength is harder to match, similar therapeutic regimens can displace demand.
Formulation barriers that can still matter
- Stability and dissolution profile consistency at scaled manufacturing.
- Tablet hardness, disintegration time, and impurity control.
- Reproducible content uniformity for a low-dose reserpine component.
Investment implication
- In a generic-heavy environment, differentiation must show up as availability, price stability, and regulatory cleanliness, not IP.
What formulation patents are likely to matter for HYDRO-SERP 50 tablets (composition, excipients, manufacturing)?
Featured snippet answer: For fixed-dose antihypertensive tablets, the most valuable patent hooks tend to be tablet composition and manufacturing method rather than new pharmacology, but an actual HYDRO-SERP 50 formulation patent list cannot be produced from the provided input.
Typical formulation IP categories in FDC legacy products
- Coated vs uncoated tablet systems controlling dissolution.
- Binder/filler selection for reserpine content uniformity.
- Moisture control excipients to manage degradation.
- Granulation method controls to stabilize dissolution and impurity profile.
What to test as an investor
- Manufacturing robustness: whether the sponsor has redundant validated lines.
- Regulatory record: inspection outcomes, batch failures, recalls.
- Documentation defensibility: DMFs/ASMFs supporting API and excipients.
What method-of-use patents could restrict HYDRO-SERP 50 generics or label substitutions?
Featured snippet answer: Method-of-use patent relevance cannot be evaluated for HYDRO-SERP 50 without jurisdiction-specific patent mapping.
How method-of-use patents usually play out
- If an FDC’s indication is broad (hypertension), method claims can be narrow and harder to enforce against generic label substitutions.
- In practice, generics often win on labeling carve-outs unless the original is tied to a specific dosing regimen that regulators require.
What FDA regulatory status and filing pathway applies to HYDRO-SERP 50?
Featured snippet answer: FDA pathway status cannot be confirmed from the provided information.
Investment relevance
- US regulatory route (if applicable) changes the “entry time to loss of exclusivity” and the expected litigation cadence.
- For off-patent combinations, the key risk is whether multiple ANDA/505(j) opportunities already exist or are blocked by reference product availability and labeling.
Which companies compete with HYDRO-SERP 50 and how does HYDRO-SERP 50 compare with alternative antihypertensive combinations?
Featured snippet answer: HYDRO-SERP 50 competes against both single-agent generics (thiazide alone, reserpine alone where available) and more modern fixed-dose combinations commonly preferred in updated clinical pathways.
Competitive map (investment-relevant)
- Thiazide monotherapy brands/generics: price anchors with high substitution likelihood.
- Modern combination regimens: ACE/ARB + thiazide; ARB + CCB; ACE/ARB + CCB; typically perceived as better tolerated and aligned with guideline preference.
- Other older combinations: competitive overlap depends on local access and reimbursement.
What investors should stress-test
- Is HYDRO-SERP 50 protected by tender contracts or hospital formularies?
- Does the product hold a cost advantage large enough to offset prescriber preference for modern combos?
- Are there documented shortage events that create temporary pricing power?
What patent litigation affects HYDRO-SERP 50 and what settlement patterns matter for future pricing?
Featured snippet answer: Specific litigation and settlement data for HYDRO-SERP 50 cannot be produced from the provided input.
How to incorporate litigation risk into the investment model
- If patent listings exist in a major market: model Paragraph IV filing risk, automatic stay behavior, and probable settlement-to-authorized generic structures.
- If no patent listings: litigation risk drops, and generic substitution becomes the primary driver.
How should investors value HYDRO-SERP 50 fundamentals under a genericization scenario?
Featured snippet answer: The valuation should be anchored on brand-level unit demand and supply stability under rapid generic substitution, not on patent-based cash-flow protection.
Base-case financial mechanics to model
- Gross margin: thickness depends on whether the manufacturer has captive procurement of APIs and excipients and whether pricing is regulated by tenders.
- Volume trajectory: assume share erosion once any equivalent combination enters or once formularies shift.
- Operating leverage: marketing and pharmacovigilance costs scale with volume; distribution costs are semi-fixed.
- Working capital: tablet businesses can be sensitive to lead times for API and excipients, especially if multiple suppliers are constrained.
Key sensitivity variables
- Pricing: % decline per new generic entrant.
- Volume elasticity: share loss rates if substitutions are clinically and policy supported.
- Regulatory disruptions: batch rejections, inspection outcomes, label change approvals.
What geographic coverage and regulatory barriers determine whether HYDRO-SERP 50 stays profitable?
Featured snippet answer: Profit persistence depends on where the product has durable reimbursement and where generic substitution is slow due to regulatory barriers or tender lock-in.
Geography-specific drivers
- Tender system structure: contract cycles determine how quickly substitution occurs.
- Registration lead times: generic registrations require local dossiers and bioequivalence where mandated.
- Labeling and safety communications: reserpine-related warnings can affect prescriber acceptance, which can either reduce demand or limit substitution if competitors avoid similar labeling.
Investor takeaway
- Treat the product as a market-penetration asset. Valuation is highest in regions where the product is already embedded and low-cost substitutions face administrative delay.
How strong is the competitive moat for HYDRO-SERP 50 given typical FDC dynamics?
Featured snippet answer: The moat is usually weak in IP terms for legacy antihypertensive fixed-dose tablets. The durable advantages are commercial and operational: supply reliability, formulary status, and procurement economics.
Moat components
- Manufacturing capability: consistent dissolution and stability.
- Regulatory compliance: low recall and inspection risk.
- Distribution: depth in primary-care channels and tender procurement visibility.
- Brand persistence: patient and physician familiarity, especially where older regimens remain in use.
Key Takeaways
- HYDRO-SERP 50 is a fixed-dose hypertension tablet combining hydrochlorothiazide 50 mg and reserpine 0.5 mg.
- The investment case is fundamentally genericization-prone; most upside must come from commercial entrenchment and supply reliability, not patent duration.
- A defensible valuation requires mapped IP and regulatory exclusivity by jurisdiction, but that mapping is not available from the provided input.
- The most critical diligence areas are formulary/tender durability, expected pricing declines under generic substitution, manufacturing compliance risk, and regulatory stability of the specific FDC strength.
FAQs
1) Is HYDRO-SERP 50 considered an older antihypertensive regimen, and does that increase substitution risk?
Yes. Older thiazide + reserpine fixed-dose regimens generally face higher substitution from more guideline-aligned modern combinations, increasing generic and therapeutic switching risk.
2) What are the biggest non-IP risks to HYDRO-SERP 50 profitability?
Regulatory compliance events (batch failures, labeling updates), tender-driven price resets, supply interruptions, and safety communication impacts on physician prescribing.
3) Can HYDRO-SERP 50 face generic competition even if exact strength is not widely replicated?
Yes. Clinically equivalent BP-lowering strategies and other fixed-dose combinations can displace use even without exact-strength matching.
4) What operational factor most influences pricing power for legacy FDC tablets?
Supply reliability and tender procurement relationships. In these products, consistent availability often matters as much as brand demand.
5) Does the presence of reserpine materially affect market adoption?
Reserpine’s historical CNS-related adverse event profile can limit adoption in markets where clinicians prefer better-tolerated alternatives, reducing brand resilience.
References
(0) No source documents were provided in the prompt to cite.
More… ↓
